{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Nguyen VC"],"pubmed_abstract":["<h4>Background</h4>Late detection of hepatocellular carcinoma (HCC) results in an overall 5-year survival rate of less than 16%. Liquid biopsy (LB) assays based on detecting circulating tumor DNA (ctDNA) might provide an opportunity to detect HCC early noninvasively. Increasing evidence indicates that ctDNA detection using mutation-based assays is significantly challenged by the abundance of white blood cell-derived mutations, non-tumor tissue-derived somatic mutations in plasma, and the mutational tumor heterogeneity.<h4>Methods</h4>Here, we employed concurrent analysis of cancer-related mutations, and their fragment length profiles to differentiate mutations from different sources. To distinguish persons with HCC (PwHCC) from healthy participants, we built a classification model using th"],"journal":["BMC cancer"],"pagination":["233"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10009971"],"repository":["biostudies-literature"],"pubmed_title":["Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma."],"pmcid":["PMC10009971"],"pubmed_authors":["Nguyen HHT","Nguyen TD","Pham TTT","Huynh LAK","Phu DTB","Nguyen TH","Nguyen CM","Truong DK","Nguyen VC","Giang H","Phan TH","Ho TD","Phan MD","Tran LS","Nguyen QB","Kim VV","Nguyen BT","Do TT","Tran TT","Nguyen HN","Tran VU","Bach HT","Phan BHH","Tran TTT","Nguyen QT","Duong ML","Pham TA","Nguyen TNV"],"additional_accession":[]},"is_claimable":false,"name":"Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.","description":"<h4>Background</h4>Late detection of hepatocellular carcinoma (HCC) results in an overall 5-year survival rate of less than 16%. Liquid biopsy (LB) assays based on detecting circulating tumor DNA (ctDNA) might provide an opportunity to detect HCC early noninvasively. Increasing evidence indicates that ctDNA detection using mutation-based assays is significantly challenged by the abundance of white blood cell-derived mutations, non-tumor tissue-derived somatic mutations in plasma, and the mutational tumor heterogeneity.<h4>Methods</h4>Here, we employed concurrent analysis of cancer-related mutations, and their fragment length profiles to differentiate mutations from different sources. To distinguish persons with HCC (PwHCC) from healthy participants, we built a classification model using th","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-29T19:43:44.866Z","creation":"2025-04-05T13:33:03.086Z"},"accession":"S-EPMC10009971","cross_references":{"pubmed":["36915069"],"doi":["10.1186/s12885-023-10681-0"]}}